22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
- Employees working for covered employers in the District of Columbia will become eligible for Unive...
Read More >
Severance and litigation settlement agreements often include a provision that prohibits one or more ...
Read More >
Effective December 31, 2019, Pennsylvania amended section 6344(m) of the Child Protective Services L...
Read More >
The Ninth Circuit recently issued two decisions in Dorman v. Charles Schwab Corp.: the first overrul...
Read More >
I’ve represented clients on both sides of freeze-out mergers of privately owned business entities, ...
Read More >
The Ministry of Manpower has issued Ministerial Decision 47/2020 (the MD). The MD adds "sales repres...
Read More >